By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Chugai Pharmaceutical Co., Ltd. (Japan) 

1-9, Kyobashi 2-chome

Chuo-ku  Tokyo  104-8301  Japan
Phone: 81-3-3281-6611 Fax: 81-3-3281-2828




Company News
Chugai Pharma's Bispecific Antibody "ACE910/Emicizumab" Phase I Data In Patients With Hemophilia A Published In The New England Journal of Medicine Online 5/26/2016 11:30:26 AM
Comprehensive Collaboration Agreement Between Osaka University And Chugai Pharma 5/19/2016 12:08:04 PM
Chugai Pharma To Present Japanese Phase III Results On Alecensa At ASCO 5/19/2016 12:03:06 PM
Chugai Pharma Announces Phase II Global Study Results Of Nemolizumab (CIM331) In Late-Breaking Research Forums At AAD 3/7/2016 11:30:40 AM
Chugai Pharma's Alecensa Trial Stopped Early After Successfully Meeting Primary Endpoint 2/10/2016 6:08:26 AM
Chugai Pharmaceutical Co., Ltd. (Japan)'s ALK Inhibitor "Alecensa" Accelerated Approval In Three Months After Priority Review Designation In The US 12/14/2015 1:20:53 PM
Chugai Pharmaceutical Co., Ltd. (Japan) Marketing Changed Its Corporate Name To Chugai Pharma Europe 11/30/2015 1:29:14 PM
Company Profile For Chugai Pharmaceutical Co., Ltd. (Japan) 10/2/2015 10:20:25 AM
Chugai Pharmaceutical Co., Ltd. (Japan)'s Bispecific Antibody "ACE910" For The Treatment Of Hemophilia A Designated As A Breakthrough Therapy By The FDA 9/4/2015 9:37:15 AM
Athersys, Inc. (ATHX) And Chugai Pharmaceutical Co., Ltd. (Japan) Enter License Agreement And Collaboration To Develop Multistem Cell Therapy For Ischemic Stroke In Japan 3/2/2015 7:12:37 AM